TTC21A: A Potential Drug Target and Biomarker (G199223)

Target Name: TTC21A

NCBI ID: G199223

TTC21A

TTC21A: A Potential Drug Target and Biomarker

TTC21A is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the TTC21 family, which includes several related proteins that are involved in various cellular processes, including cell signaling, DNA replication, and apoptosis. One of the unique features of TTC21A is its ability to interact with the protein p53, which is a well-known tumor suppressor protein that plays a critical role in maintaining genomic stability and regulating cell growth and apoptosis.

The research on TTC21A has primarily focused on its potential role as a drug target and biomarker. Several studies have demonstrated that TTC21A can be targeted by small molecules, including inhibitors of the protein's tyrosine kinase activity, which is known to be a key step in the signaling cascade that regulates various cellular processes. Additionally, TTC21A has been shown to play a role in the regulation of cell proliferation and apoptosis, which are important processes that are altered in many types of cancer.

One of the most promising aspects of TTC21A as a drug target is its potential to target a wide range of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its role in these processes makes it an attractive target for small molecule inhibitors, which can be used to treat a variety of diseases that affect millions of people worldwide.

In addition to its potential as a drug target, TTC21A has also been shown to be a potential biomarker for several types of cancer. Its expression has been detected in a variety of cancer tissues, including breast, ovarian, and colorectal cancers, and has been shown to be associated with poor prognosis in these diseases. Additionally, studies have suggested that TTC21A may be a useful biomarker for monitoring the effectiveness of cancer treatments, as its expression has been shown to be sensitive to the effects of certain therapies.

The identification of TTC21A as a potential drug target and biomarker has important implications for the development of new treatments for a variety of diseases. While further research is needed to fully understand its role in these processes, its potential as a drug target and biomarker is an exciting area of research that could lead to new treatments for some of the most devastating diseases.

Protein Name: Tetratricopeptide Repeat Domain 21A

Functions: Intraflagellar transport (IFT)-associated protein required for spermatogenesis (PubMed:30929735). Required for sperm flagellar formation and intraflagellar transport (PubMed:30929735)

The "TTC21A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC21A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets